Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
TH Open ; 4(2): e127-e137, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32607466

RESUMO

Introduction There is scarce real-world experience regarding direct oral anticoagulants (DOACs) perioperative management. No study before has linked bridging therapy or DOAC-free time (pre-plus postoperative time without DOAC) with outcome. The aim of this study was to investigate real-world management and outcomes. Methods RA-ACOD is a prospective, observational, multicenter registry of adult patients on DOAC treatment requiring surgery. Primary outcomes were thrombotic and hemorrhagic complications. Follow-up was immediate postoperative (24-48 hours) and 30 days. Statistics were performed using a univariate and multivariate analysis. Data are presented as odds ratios (ORs [95% confidence interval]). Results From 26 Spanish hospitals, 901 patients were analyzed (53.5% major surgeries): 322 on apixaban, 304 on rivaroxaban, 267 on dabigatran, 8 on edoxaban. Fourteen (1.6%) patients suffered a thrombotic event, related to preoperative DOAC withdrawal (OR: 1.57 [1.03-2.4]) and DOAC-free time longer than 6 days (OR: 5.42 [1.18-26]). Minor bleeding events were described in 76 (8.4%) patients, with higher incidence for dabigatran (12.7%) versus other DOACs (6.6%). Major bleeding events occurred in 17 (1.9%) patients. Bridging therapy was used in 315 (35%) patients. It was associated with minor (OR: 2.57 [1.3-5.07]) and major (OR: 4.2 [1.4-12.3]) bleeding events, without decreasing thrombotic events. Conclusion This study offers real-world data on perioperative DOAC management and outcomes in a large prospective sample size to date with a high percentage of major surgery. Short-term preprocedural DOAC interruption depending on the drug, hemorrhagic risk, and renal function, without bridging therapy and a reduced DOAC-free time, seems the safest practice.

2.
Paediatr Anaesth ; 14(2): 172-5, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-14962334

RESUMO

We present the case of a neonate undergoing surgery on the first day of life for the installation of a permanent pacemaker because of the existence of congenital complete heart block (CCHB) with a basal heart rate of 43 b.min(-1) and minimal elevation after initiating an isoproterenol perfusion. The intervention was under general anaesthesia with laryngeal mask airway (LMA) and spontaneous ventilation. The principal anaesthetic goals were to assure adequate anaesthesia, with haemodynamic and respiratory stability, to maintain the best possible heart rate and to avoid postoperative respiratory depression or apnoea.


Assuntos
Anestesia Geral/métodos , Bloqueio Cardíaco/congênito , Bloqueio Cardíaco/cirurgia , Ketamina/uso terapêutico , Éteres Metílicos/uso terapêutico , Analgésicos/efeitos adversos , Analgésicos/uso terapêutico , Anestésicos Inalatórios/efeitos adversos , Anestésicos Inalatórios/uso terapêutico , Apneia/prevenção & controle , Bloqueio Cardíaco/etiologia , Frequência Cardíaca/fisiologia , Humanos , Recém-Nascido , Ketamina/efeitos adversos , Máscaras Laríngeas , Lúpus Eritematoso Sistêmico/complicações , Masculino , Éteres Metílicos/efeitos adversos , Marca-Passo Artificial , Complicações Pós-Operatórias/prevenção & controle , Sevoflurano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA